A Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer(PANKU-Lung06)
Clinical trial NCT07739186 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07739186
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2026-08-01
- Primary completion
- 2029-12-01
- Enrollment
- 120
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.